MedTrace Logo

Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19

NCT04910230 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-11-08

No results posted yet for this study

Summary

The mechanism of peripheral blood lymphocyte decline in COVID-19 patients is not yet clear. However, one theory demonstrated that in the whole progression of COVID-19, the extensive activation of poly-ADP-ribose polymerase (PARP) may reduce the cellular NAD+ and dampen the adaptive immune system. So investigators presume that replenishing the NAD+ using nicotinamide as the precursor may improve the lymphocyte counts and boost the adaptive immune system. As a result, the study using nicotinamide as a kind of supportive therapy provide further evidence of their efficiency and safety in treating lymphopenia in patients with COVID-19.

Conditions

Interventions

DRUG

nicotinamide

In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses

Sponsors & Collaborators

  • Qiang Hu

    lead OTHER

Principal Investigators

  • Quan-Yu L Zhang, phD · Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-04-02
Completion
2020-04-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910230 on ClinicalTrials.gov